|1.||Kusunoki, Masato: 5 articles (01/2011 - 01/2005)|
|2.||Uchida, Keiichi: 5 articles (01/2011 - 01/2005)|
|3.||Mohri, Yasuhiko: 4 articles (01/2011 - 01/2005)|
|4.||Miki, Chikao: 4 articles (10/2008 - 01/2005)|
|5.||Inoue, Mikihiro: 3 articles (01/2011 - 08/2005)|
|6.||Inoue, Yasuhiro: 3 articles (10/2008 - 01/2005)|
|7.||Lee, Won-Suk: 2 articles (09/2013 - 03/2009)|
|8.||Otake, Kohei: 2 articles (01/2011 - 10/2008)|
|9.||Arai, Mikki: 2 articles (03/2009 - 03/2006)|
|10.||Sueda, Jun: 2 articles (03/2009 - 03/2006)|
10/01/2005 - "The placement of Seprafilm helped to prevent EPSBO and had no significant adverse affect on surgical site infections."
09/01/2012 - "However, laparoscopic examinations in these 2 patients revealed only gel-like hydrated Seprafilm without evidence of infection. "
01/01/2011 - "Seprafilm may improve the safety of VP shunt reinsertion and preserve the function of the reinserted VP shunt after VP shunt malfunction with infection."
01/01/2010 - "The incidence of surgical infection showed no significant difference between the Seprafilm group (3.6%) and the control group (6.7%). "
10/01/2005 - "The incidence of surgical site infection between the Seprafilm (15.2%) and control (13.7%) groups was not statistically significant. "
|2.||Wounds and Injuries (Trauma)
08/01/2000 - "Seprafilm is highly effective in preventing adhesions to PPM. This effect was not diminished by the presence of visceral trauma and its resultant inflammatory response. "
05/01/2009 - "Retrospective case series of 4 consecutive patients with trap door orbital wall fractures secondary to blunt trauma with entrapped orbital soft tissue who underwent surgical repair with placement of Seprafilm implant in 2008. "
05/01/2008 - "Before closing the abdominal incision, 2 sheets of Seprafilm membrane were applied to the surface of the small intestine under the middle abdominal wound in the Seprafilm group. "
02/01/2004 - "Seprafilm protects peritoneal wounds by physically covering the injured peritoneum. "
10/01/2003 - "Patients received an average of 4.4 and as many as 10 Seprafilm adhesion barriers applied to organs and tissue surfaces that sustained direct surgical trauma and to suspected adhesiogenic surfaces. "
|3.||Intestinal Obstruction (Obstruction, Intestinal)
05/01/2001 - "During short-term follow-up in this nonprospective, nonrandomized study, limited placement of Seprafilm did not significantly reduce the need for surgical enterolysis for intestinal obstruction or significantly adversely affect the morbidity rate. "
03/01/2009 - "Five patients in the Seprafilm group experienced postoperative intestinal obstruction (2.7%) compared with 11 patients in the control group (4.6%) during the follow-up period; however, there was no statistical difference. "
03/01/2009 - "There were no differences in the incidence of complications between the two groups; however, the incidence of early postoperative intestinal obstruction was significantly less in the Seprafilm group than in the control group (2.7% vs 7.0%, respectively, p = 0.045). "
11/01/2007 - "Our systematic review and meta-analysis showed that Seprafilm could decrease abdominal adhesions after general surgery, which may benefit patients, but could not reduce postoperative intestinal obstruction. "
11/01/2007 - "The incidence of intestinal obstruction after abdominal surgery was not different between Seprafilm and control groups (OR 95%CI, 0.78-1.23; p = 0.84). "
10/01/2002 - "Our study suggests that the Sepracoat reduces the incidence and severity of abdominal adhesions following laparoscopic mesh insertion and should be considered as a prophylactic agent, especially in those undergoing laparoscopic transabdominal mesh repair for hernia."
01/01/2000 - "HAM and Seprafilm proved to be an effective antiadhesive barrier in PPM repair of abdominal wall hernia."
01/01/2000 - "Evaluation of seprafilm and amniotic membrane as adhesion prophylaxis in mesh repair of abdominal wall hernia in rats."
02/01/1999 - "Re: Prevention of adhesions by Seprafilm, an absorbable adhesions barrier: an incisional hernia model in rats."
09/01/1997 - "Prevention of adhesions by Seprafilm, an absorbable adhesion barrier: an incisional hernia model in rats."
|5.||Colorectal Neoplasms (Colorectal Cancer)
10/01/2002 - "Seprafilm did not adversely affect the short-term recurrence rate after curative resection of colorectal cancer. "
10/01/2002 - "Seprafilm: a retrospective preliminary evaluation of the impact on short-term oncologic outcome in colorectal cancer."
03/01/2009 - "Seprafilm appears to be effective in preventing early postoperative intestinal obstruction and there was a trend for reduced intestinal obstruction after lower abdominal surgery for colorectal cancer."
03/01/2009 - "This study is a prospective randomized clinical trial to evaluate the clinical safety and the effect of a sodium hyaluronate-based bioresorbable membrane (Seprafilm; Genzyme, Cambridge, MA, USA) for reducing adhesive intestinal obstruction after colorectal cancer surgery. "
03/01/2009 - "Sodium hyaluronate-based bioresorbable membrane (Seprafilm) reduced early postoperative intestinal obstruction after lower abdominal surgery for colorectal cancer: the preliminary report."
|1.||Hyaluronic Acid (Hyaluronan)
|2.||Carboxymethylcellulose Sodium (Polycell)
|6.||Biocompatible Materials (Biomaterials)
|10.||Leukocyte Elastase (Neutrophil Elastase)
|2.||Lymph Node Excision (Lymph Node Dissection)
|4.||Surgical Instruments (Clip)